Literature DB >> 14766412

Down-regulation of the GTPase RhoB might be involved in the pre-apoptotic phenotype of osteoarthritic chondrocytes.

Pia M Gebhard1, Stephan Söder, Brigitte Bau, Thomas Aigner.   

Abstract

Anabolic activity, phenotypic alterations, and in particular survival of the chondrocytes are essential for the maintenance of proper articular cartilage and appears to fail during osteoarthritic cartilage degeneration. In this study, we investigated the presence and expression of RhoB in adult human articular cartilage and its regulation in osteoarthritic cartilage as well as in chondrocytes in vitro. RhoB belongs to the family of small GTPases, which are thought to be involved in a large range of activities important for eukaryotic cells. Conventional and quantificative PCR analysis showed significant levels of RhoB expression in normal articular cartilage. Immunolocalization and confocal laser scanning microscopy showed strong cytoplasmic signals for RhoB in normal chondrocytes. In osteoarthritic cartilage, a significantly lower expression of RhoB was detectable. In vitro experiments showed a quick (and transient) up-regulation of RhoB after stimulation with interleukin-1beta and serum. Our study suggests that RhoB is constitutively expressed and essential for adult articular chondrocytes, but significantly down-regulated in osteoarthritic chondrocytes. One intriguing speculation might be that the down-regulation of RhoB in osteoarthritic chondrocytes is at least partly a prerequisite for the sustained pre- or para-apoptotic phenotype of osteoarthritic chondrocytes, because RhoB is known to be one important molecule in the induction of apoptotic cell death in response to DNA damage and osteoarthritic chondrocytes are known to have significant DNA damage. Alternatively, RhoB could be involved in the activation or deactivation and the destabilization of the functional phenotype of chondrocytes in osteoarthritic joint degeneration Thirdly, RhoB is associated with the cell cycle, which is re-initiated in osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14766412     DOI: 10.2741/1254

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  6 in total

1.  Cis- and trans-acting gene regulation is associated with osteoarthritis.

Authors:  Sandra Mahr; Gerd-Rüdiger Burmester; Dietmar Hilke; Udo Göbel; Andreas Grützkau; Thomas Häupl; Matthias Hauschild; Dirk Koczan; Veit Krenn; Jasper Neidel; Carsten Perka; Andreas Radbruch; Hans-Jürgen Thiesen; Brigitte Müller
Journal:  Am J Hum Genet       Date:  2006-03-22       Impact factor: 11.025

2.  Identification of a role for the ARHGEF3 gene in postmenopausal osteoporosis.

Authors:  Ben H Mullin; Richard L Prince; Ian M Dick; Deborah J Hart; Tim D Spector; Frank Dudbridge; Scott G Wilson
Journal:  Am J Hum Genet       Date:  2008-05-22       Impact factor: 11.025

Review 3.  Wnt and Rho GTPase signaling in osteoarthritis development and intervention: implications for diagnosis and therapy.

Authors:  Shouan Zhu; Huanhuan Liu; Yan Wu; Boon Chin Heng; Pengfei Chen; Hua Liu; Hong Wei Ouyang
Journal:  Arthritis Res Ther       Date:  2013-07-11       Impact factor: 5.156

Review 4.  Rho GTPase signaling in rheumatic diseases.

Authors:  Ruijie Zeng; Zewei Zhuo; Yujun Luo; Weihong Sha; Hao Chen
Journal:  iScience       Date:  2021-12-14

5.  Gene Expression Microarray Data Identify Hub Genes Involved in Osteoarthritis.

Authors:  Jian Zhou; Dazhi Zou; Rongjun Wan; Jie Liu; Qiong Zhou; Zhen Zhou; Wanchun Wang; Cheng Tao; Tang Liu
Journal:  Front Genet       Date:  2022-06-06       Impact factor: 4.772

6.  Association of single-nucleotide polymorphisms in RHOB and TXNDC3 with knee osteoarthritis susceptibility: two case-control studies in East Asian populations and a meta-analysis.

Authors:  Dongquan Shi; Takahiro Nakamura; Masahiro Nakajima; Jin Dai; Jianghui Qin; Haijian Ni; Yong Xu; Chen Yao; Jia Wei; Baorui Liu; Shiro Ikegawa; Qing Jiang
Journal:  Arthritis Res Ther       Date:  2008-05-10       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.